TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03528915

Intervention type: OTHER
Intervention: Rifamycine treatment
Description: Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.

Intervention type: OTHER
Intervention: whithout Rifamycine treatment
Description: Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
Study: NCT02454556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLITIME®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F®
Study: NCT02734394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiovascular and resistance exercise training
Study: NCT02474004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial meniscal surgery
Description: one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial meniscal surgery
Description: one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
Study: NCT00680134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 1% Solution, once daily for 180 days
Study: NCT01638546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00680134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
Study: NCT00671853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for quetiapine XR
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
Study: NCT02008214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Addition of pentoxifylline to current HCV treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching pentoxifylline dosage
Study: NCT03414294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part B (MAD)
Description: Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part B (MAD)
Description: Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part C (FE)
Description: Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part D (FE)
Description: Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part E (MAD)
Description: Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part E (MAD)
Description: Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study: NCT01371227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS002
Description: 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
Study: NCT00511823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study: NCT04690244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan trainings
Description: 10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
Study: NCT03313336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA test patch
Description: EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA current reference patch
Description: EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
Study: NCT01705678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: Krill oil 300 mg DHA/EPA daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil 500 mg DHA/EPA daily for 6 weeks
Study: NCT05241145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED-80
Description: Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
Study: NCT00511823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study: NCT03778476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
Study: NCT05094258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unicondylar knee prosthesis with mobile insert
Description: Patients with unicondylar knee replacement using the mobile insert option

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unicondylar knee prosthesis with fixed insert
Description: Patients with unicondylar knee replacement using the fixed insert option
Study: NCT04084275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding education
Study: NCT05241145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED-80
Description: Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
Study: NCT01088022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant, Palonosetron, Dexamethasone
Description: Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study: NCT04084275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal hygiene education
Description: In this training, the puerpera was informed about personal hygiene to prevent infection.
Study: NCT01088022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Palonosetron, Dexamethasone
Description: Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study: NCT01824186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC
Description: Underwent conventional 4-port laparoscopic cholecystectomy
Study: NCT00898391

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Intervention: polyacrylamide gel electrophoresis
Description: Correlative studies

Intervention type: GENETIC
Intervention: DNA analysis
Description: Correlative studies
Study: NCT02238834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025
Description: Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025
Description: Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
Study: NCT02149017

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SNUBH-NM-333(18F)
Description: 5-10 mCi
Study: NCT00389675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Guanfacine 1 mg capsules administered orally once daily
Study: NCT04322825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS incorporated into the Mollii suit
Description: trans cutaneous electric stimulation,
Study: NCT03921177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement
Description: Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Preconception to 12-weeks gestation: identical tablet
Study: NCT04190277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop condition
Description: Patient's standard insulin pump setting combined with continuous glucose monitoring sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop condition
Description: Patient's standard insulin pump setting combined with continuous glucose monitoring sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop condition
Description: Closed-loop algorithm system paired with continuous glucose monitoring sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop condition
Description: Closed-loop algorithm system paired with continuous glucose monitoring sensor
Study: NCT04316364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Description: Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316、Chemotherapeutic
Description: Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo、Chemotherapeutic
Description: Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
Study: NCT03574428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Monoclonal Antibody infused i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Monoclonal Antibody infused i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Monoclonal Antibody infused i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Monoclonal Antibody infused i.v.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1 Placebo
Description: Equivalent to GNbAC1 Buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1 Placebo
Description: Equivalent to GNbAC1 Buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1 Placebo
Description: Equivalent to GNbAC1 Buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1 Placebo
Description: Equivalent to GNbAC1 Buffer
Study: NCT04916379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Momordica charantia
Description: Momordica Charantia: 2000 mg per day for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2000 mg per day for 12 weeks
Study: NCT04412447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
Study: NCT03030339

Intervention type: OTHER
Intervention: High VA intake, recent VAS
Description: Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.

Intervention type: OTHER
Intervention: High VA intake
Description: Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.

Intervention type: OTHER
Intervention: Low/adequate VA intake
Description: Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
Study: NCT02161107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass-SPIRE
Description: Intradermal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass-SPIRE
Description: Intradermal injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection
Study: NCT01722435

Intervention type: DRUG
Intervention: Opiate Substitution Treatment
Study: NCT03507712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetrical IO weakening
Description: Bilateral IO Myectomy / Bilateral equal graded IO Recession

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical IO weakening
Description: IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
Study: NCT03524807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiologic therapy
Description: Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
Study: NCT03704961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and audiobook listening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and audiobook listening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and audiobook listening
Study: NCT03458533

Intervention type: PROCEDURE
Intervention: Bariatric surgery

Intervention type: BEHAVIORAL
Intervention: Diet and lifestyle changes

Intervention type: BEHAVIORAL
Intervention: Diet and lifestyle changes
Study: NCT02245841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: 80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
Study: NCT00481195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
Study: NCT01960946

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Citrus Pectin (MCP) vs placebo
Description: 5 grams by mouth three times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified Citrus Pectin (MCP) vs placebo
Description: 5 grams by mouth three times a day
Study: NCT02290106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT02876900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Asenapine maleate transdermal patch
Description: The study will evaluate low dose Asenapine maleate transdermal patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Asenapine maleate transdermal patch
Description: The study will evaluate high dose Asenapine maleate transdermal patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study will evaluate placebo transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study will evaluate placebo transdermal patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will evaluate placebo transdermal patch.
Study: NCT03961542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing
Description: Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
Study: NCT00370253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: 1mg/4 h per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: 0,1 mcg/kg/min
Study: NCT02141997

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: adalimumab administered as subcutaneous injection every other week (EOW)
Study: NCT04288661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No drain placement
Description: The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered